Patents by Inventor Laimonis Kelbauskas

Laimonis Kelbauskas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230050322
    Abstract: A classification training method for training classifiers adapted to identify specific mutations associated with different cancer including identifying driver mutations. First cells from mutation cell lines derived from conditions having the number of driver mutations are acquired and 3D image feature data from the number of first cells is identified. 3D cell imaging data from the number of first cells and from other malignant cells is generated, where cell imaging data includes a number of first individual cell images. A second set of 3D cell imaging data is generated from a set of normal cells where the number of driver mutations are expected to occur, where the second set of cell imaging data includes second individual cell images. Supervised learning is conducted based on cell line status as ground truth to generate a classifier.
    Type: Application
    Filed: October 18, 2022
    Publication date: February 16, 2023
    Inventors: Michael G. Meyer, Daniel J. Sussman, Rahul Katdare, Laimonis Kelbauskas, Alan C. Nelson, Randall Mastrangelo
  • Publication number: 20210210169
    Abstract: A classification training method for training classifiers adapted to identify specific mutations associated with different cancer including identifying driver mutations. First cells from mutation cell lines derived from conditions having the number of driver mutations are acquired and 3D image feature data from the number of first cells is identified. 3D cell imaging data from the number of first cells and from other malignant cells is generated, where cell imaging data includes a number of first individual cell images. A second set of 3D cell imaging data is generated from a set of normal cells where the number of driver mutations are expected to occur, where the second set of cell imaging data includes second individual cell images. Supervised learning is conducted based on cell line status as ground truth to generate a classifier.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 8, 2021
    Applicant: VISIONGATE, INC.
    Inventors: Michael G. MEYER, Daniel J. SUSSMAN, Rahul KATDARE, Laimonis KELBAUSKAS, Alan C. NELSON, Randall MASTRANGELO
  • Publication number: 20210049425
    Abstract: A method for a system and method for morphometric detection of malignancy associated change (MAC) is disclosed including the acts of obtaining a sample; imaging cells to produce 3D cell images for each cell; measuring a plurality of different structural biosignatures for each cell from its 3D cell image to produce feature data; analyzing the feature data by first using cancer case status as ground truth to supervise development of a classifier to test the degree to which the features discriminate between cells from normal or cancer patients; using the analyzed feature data to develop classifiers including, a first classifier to discriminate normal squamous cells from normal and cancer patients, a second classifier to discriminate normal macrophages from normal and cancer patients, and a third classifier to discriminate normal bronchial columnar cells from normal and cancer patients.
    Type: Application
    Filed: February 28, 2019
    Publication date: February 18, 2021
    Applicant: VISIONGATE, INC.
    Inventors: Michael G. Meyer, Laimonis Kelbauskas, Rahul Katdare, Daniel J. Sussman, Timothy Bell, Alan C. Nelson
  • Publication number: 20200370130
    Abstract: A method to develop one or more morphometric classifiers to identify a tumor mutation burden (TMB). The method provides a non-invasive method of characterizing TMB that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.
    Type: Application
    Filed: January 4, 2019
    Publication date: November 26, 2020
    Applicant: VISIONGATE, INC.
    Inventors: Daniel J. Sussman, Michael Meyer G. Meyer, Laimonis Kelbauskas, Alan C. Nelson, Randall Mastrangelo